Course Objectives
In this 5-session course, we will explore clinically significant pharmacokinetic drug-drug interactions (DDIs) observed with recently FDA approved drug therapies. The possible mechanisms (e.g., inhibition or induction of metabolizing enzymes and/or transporters, changes in drug absorption, pharmacogenetics, organ impairment) will be reviewed and potential clinical outcomes explained. Mitigation strategies to prevent or minimize the risk of DDIs will be discussed.
At the end of this course, students will be able to:
- Understand the basic scientific principles of drug metabolism and drug transport and their roles in controlling drug exposure and pharmacokinetic drug-drug interactions;
- Review the main mechanisms involved in pharmacokinetic drug-drug interactions;
- Understand the concepts of marker, victim, and perpetrator drugs and know how to extrapolate the results of a marker study to common co-medications;
- Know the categorization of clinical victim and perpetrator drugs sensitivity and potency (weak, moderate, or strong) and the impact on product labeling recommendations;
- Describe common drug interactions with recently approved drug therapies;
- Examine significant drug interactions observed during the drugs’ development and discuss likely mechanism(s) and possible clinical outcomes;
- Apply mechanistic knowledge gained to predict and prevent drug interactions;
- Identify relevant resources to develop a risk mitigation strategy.
Instructors
Cathy Yeung, PharmD, PhD, MPH, Instructor, University of Washington (UW) Drug Interaction Solutions, Department of Pharmaceutics, Seattle, WA
Jingjing Yu, MD, PhD, Principal Investigator and Instructor, University of Washington (UW) Drug Interaction Solutions, Department of Pharmaceutics, Seattle, WA
Planning Committee
Leslie Dickmann, PhD, MPH, Program Director, Division of Pharmacy Professional Development, UW-Madison School of Pharmacy, Madison, WI
Isabelle Ragueneau-Majlessi, MD, MS, Senior Advisor, University of Washington (UW) Drug Interaction Solutions, Department of Pharmaceutics, Seattle, WA